Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Clinical reaction" patented technology

Methods of treating disease with dichlorphenamide

Provided herein are methods for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) substrate to treat an associated disease or disorder. The method comprises administering to the subject a therapeutically effective amount of dichlorphenamide, or a pharmaceutically acceptable salt thereof, and monitoring the subject for signs and symptoms of toxicity and clinical response associated with the OAT1 substrate.
Owner:XERIS PHARMACEUTICALS INC

Biomarkers for diagnosing hidradenitis suppurativa

PendingJP2026510820AOrganic active ingredientsAntipyreticHidradenitisPlasma biomarkers
This disclosure provides a diagnostic method, which can be used in combination with medical intervention, that uses one or more plasma biomarkers useful for identifying subjects with hidradenitis suppurativa (HS), measures the disease severity of HS, and measures the clinical response in subjects with HS. This disclosure relates to a method for testing for hidradenitis suppurativa (HS) in a subject, comprising measuring one or more plasma biomarkers in a sample taken from the subject, wherein one or more plasma biomarkers are selected from the group consisting of IL8, IL36β, MDC, and TNFα.
Owner:AMGEN INC

Food allergen composition

The present invention relates to food allergen compositions. In particular, the present invention relates to novel compositions and methods for the diagnosis or treatment of food allergies. Specifically, the present invention discloses a novel method of delivering food allergens to an allergic patient by oral administration of a formulation that dissolves and releases the proteins in the stomach. The present invention allows for the treatment of food allergies by delivering food allergens to the intestinal immune system and controlled exposure to the esophagus or oral cavity. The present invention also allows for the assessment of the threshold of clinical reactivity by food provocation without exposure to the esophagus and oral cavity. The present invention can be used in any subject, particularly a human subject, and is applicable to any food allergen.
Owner:DBV TECH INC